The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of rosuvastatin combined with chemoradiation therapy (CRT) in the treatment of high-risk locally advanced rectal cancer (STARC trial).
 
Jose Gerard Monzon
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche Canada; Sanofi; Taiho Oncology
Speakers' Bureau - EMD Serono; Merck; Novartis
Research Funding - Merck (Inst)
 
Kurian Joseph
Honoraria - EMD Serono (Inst); Sanofi/Aventis
Research Funding - EMD Serono (Inst)
Travel, Accommodations, Expenses - EMD Serono
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen; Roche Canada
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada
 
Patricia A. Tang
Consulting or Advisory Role - APOBIOLOGIX; AstraZeneca; AstraZeneca; AstraZeneca Canada; Bristol-Myers Squibb; Eisai; Incyte; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Pfizer; Roche Canada; Taiho Pharmaceutical (Inst); Teva
Speakers' Bureau - Apobiologix
Travel, Accommodations, Expenses - Amgen
Other Relationship - Novartis
 
Rishi Sinha
No Relationships to Disclose
 
Kristopher Dennis
No Relationships to Disclose
 
Rachel Anne Goodwin
Honoraria - Advanced Accelerator Applications; Eisai; Ipsen; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Amgen; Apobiologix; Astellas Pharma; AstraZeneca Canada; Eisai; Incyte; Ipsen; Merck; MSD; Novartis; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical; Viatris
Speakers' Bureau - Advanced Accelerator Applications/Novartis; Amgen; Eisai; Ipsen; Merck; Mylan; Pfizer
Research Funding - Eisai; Ipsen
 
Diane Severin
No Relationships to Disclose
 
Jim Dimitroulakos
No Relationships to Disclose
 
Michael M. Vickers
No Relationships to Disclose